These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 28073851)

  • 1. Increased Risk of Adverse Neurocognitive Outcomes With Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors.
    Khan AR; Bavishi C; Riaz H; Farid TA; Khan S; Atlas M; Hirsch G; Ikram S; Bolli R
    Circ Cardiovasc Qual Outcomes; 2017 Jan; 10(1):. PubMed ID: 28073851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
    Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
    Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of PCSK9 antibodies in cardiovascular disease: Critical considerations of mortality and neurocognitive findings from the current literature.
    Kołodziejczak M; Navarese EP
    Atherosclerosis; 2016 Apr; 247():189-92. PubMed ID: 26926598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of PCSK9 inhibitors on brain stroke prevention: A systematic review and meta-analysis.
    Qin J; Liu L; Su XD; Wang BB; Fu BS; Cui JZ; Liu XY
    Nutr Metab Cardiovasc Dis; 2021 Jul; 31(8):2234-2243. PubMed ID: 34052073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PCSK9 inhibition in PAD patients - a rising star in secondary prevention?
    Vasa; 2018 Feb; 47(2):157. PubMed ID: 29460708
    [No Abstract]   [Full Text] [Related]  

  • 7. Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?
    Bittner V
    Circulation; 2016 Nov; 134(22):1695-1696. PubMed ID: 27895023
    [No Abstract]   [Full Text] [Related]  

  • 8. Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders.
    Gupta S
    Vasc Health Risk Manag; 2016; 12():421-433. PubMed ID: 27877050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What Proportion of Patients Admitted with Stroke or Transient Ischemic Attack May Be Suitable for Newer Cholesterol-Lowering Treatment?
    Alakbarzade V; Pereira AC
    J Stroke Cerebrovasc Dis; 2020 Jan; 29(1):104457. PubMed ID: 31732461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Sterol Absorption Markers in a Cohort of Real-World Patients.
    Brandt EJ; Benes LB; Lee L; Dayspring TD; Sorrentino M; Davidson M
    J Cardiovasc Pharmacol Ther; 2019 Jan; 24(1):54-61. PubMed ID: 29940784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.
    Lipinski MJ; Benedetto U; Escarcega RO; Biondi-Zoccai G; Lhermusier T; Baker NC; Torguson R; Brewer HB; Waksman R
    Eur Heart J; 2016 Feb; 37(6):536-45. PubMed ID: 26578202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
    Blom DJ; Dent R; Castro RC; Toth PP
    Vasc Health Risk Manag; 2016; 12():185-97. PubMed ID: 27274264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network.
    Chamberlain AM; Gong Y; Shaw KM; Bian J; Song WL; Linton MF; Fonseca V; Price-Haywood E; Guhl E; King JB; Shah RU; Puro J; Shenkman E; Pawloski PA; Margolis KL; Hernandez AF; Cooper-DeHoff RM
    J Am Heart Assoc; 2019 May; 8(9):e011246. PubMed ID: 31020929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors and the risk for neurocognitive adverse events: A systematic review, meta-analysis and meta-regression.
    Hirsh Raccah B; Yanovsky A; Treves N; Rotshild V; Renoux C; Danenberg H; Eliaz R; Matok I
    Int J Cardiol; 2021 Jul; 335():7-14. PubMed ID: 33892045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia.
    Dijk W; Cariou B
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 1():39-51. PubMed ID: 31002456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurological effects of proprotein convertase subtilisin/kexin type 9 inhibitors: direct comparisons.
    Bajaj NS; Patel N; Kalra R; Ahmad A; Venkatraman A; Arora G; Arora P
    Eur Heart J Qual Care Clin Outcomes; 2018 Apr; 4(2):132-141. PubMed ID: 29121222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alirocumab as add-on therapy to statins: current evidence and clinical potential.
    Auer J; Berent R
    Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial.
    Virani SS; Akeroyd JM; Nambi V; Michos ED; Morris PB; Nasir K; Smith SC; Stone NJ; Petersen LA; Ballantyne CM
    Circulation; 2019 Jan; 139(3):410-412. PubMed ID: 30586689
    [No Abstract]   [Full Text] [Related]  

  • 19. PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review.
    Handelsman Y; Lepor NE
    J Am Heart Assoc; 2018 Jun; 7(13):. PubMed ID: 29934421
    [No Abstract]   [Full Text] [Related]  

  • 20. PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention.
    Paciullo F; Momi S; Gresele P
    Thromb Haemost; 2019 Mar; 119(3):359-367. PubMed ID: 30605918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.